AbbVie has submitted an application to the FDA for the approval of TrenibotE — the first-in-class botulinum toxin type E. The product demonstrates a record-fast onset of action (8 hours) and a short duration of effect (2-3 weeks), which may change the approach to initial injections in patients who have previously avoided neurotoxins.

Sample informed consent form for the administration of Botox.

Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxin A) for the Treatment of Moderate to Severe Glabellar Lines.

Millions of botulinum toxin injections have been performed worldwide. However, not all of them were done with contraindications taken into account, and not all patients were satisfied with the results.